

NEW MOLECULAR TARGETS AND NOVEL AGENTS
FOR THE TREATMENT OF
ADVANCED RENAL CELL

CARCINOMA
FROM RATIONAL DESIGN TO CLINICAL EFFICACY

A CME/CNE REGIONAL DINNER PROGRAM SERIES

CHAIR

MICHAEL B. ATKINS, MD

Deputy Chief
Division of Hematology/Oncology
Beth Israel Deaconess Cancer Center

FACULTY

RONALD BUKOWSKI, MD

Director Experimental Therapeutics
Cleveland Clinic Taussig Cancer Center

ROBERT J. MOTZER, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center

ROBERT FIGLIN, MD

Chair, Medical Oncology & Therapeutics
City of Hope Comprehensive Cancer Center

JEFFREY A. SOSMAN, MD

Professor of Medicine
Vanderbilt Medical Center

LOCATIONS

Atlanta, GA
Bethesda, MD
Cary, NC

Chicago, IL
Dallas, TX
Detroit, MI

Houston, TX
Los Angeles, CA
Nashville, TN

New York, NY
Philadelphia, PA
Tampa, FL

PROVIDED BY |  **CBCE**



REGISTER NOW!

You can register for an activity by:

Online – www.thebcce.com/rcc to register online.

Fax – Complete the form below and fax to the CBCE™ (The Center for Biomedical Continuing Education) at (214) 260-0408.

Phone – Call: (214) 260-9024

Registrations will be confirmed via e-mail and phone. Your registration is not complete until you receive a confirmation. Please contact the CBCE via phone, (214) 260-9024, or e-mail, info@thebcce.com, if you have not received confirmation of your registration within 3 business days of your registration submission.

NEW MOLECULAR TARGETS AND NOVEL AGENTS
FOR THE TREATMENT OF

ADVANCED RENAL CELL

CARCINOMA

FROM RATIONAL DESIGN TO CLINICAL EFFICACY

A CME/CNE REGIONAL DINNER PROGRAM SERIES

PLEASE SELECT YOUR
LOCATION PREFERENCE

- Atlanta, GA
- Bethesda, MD
- Cary, NC
- Chicago, IL
- Dallas, TX
- Detroit, MI
- Houston, TX
- Los Angeles, CA
- Nashville, TN
- New York, NY
- Philadelphia, PA
- Tampa, FL

MD NP PA RN PharmD Other: _____

LAST NAME

FIRST NAME

INSTITUTE

TITLE

ADDRESS (NO P.O. BOXES)

CITY

STATE

ZIP/POSTAL CODE

TELEPHONE (FOR CONFIRMATION PURPOSES)

FAX

E-MAIL (FOR CONFIRMATION PURPOSES)

Provided by:  CBCE

AGENDA

Registration/Reception – 30 minutes
 Presentation/Dinner – 1 hour
 Question-and-Answer Session – 15 minutes
 Evaluations – 15 minutes

*Faculty and Agenda subject to change

YOU ARE CORDIALLY INVITED TO ATTEND A CONTINUING EDUCATION ACTIVITY ON:

NEW MOLECULAR TARGETS AND NOVEL AGENTS
 FOR THE TREATMENT OF

ADVANCED RENAL CELL

CARCINOMA

FROM RATIONAL DESIGN TO CLINICAL EFFICACY

A CME/CNE REGIONAL DINNER PROGRAM SERIES

	DATE	TIME	LOCATION	GUEST SPEAKER
Cary, NC	MONDAY, JANUARY 14, 2008	6:00-8:00 PM	Ruth's Chris Steakhouse The Arboretum at Weston 2010 Renaissance Park Place Cary, NC 27513	JEFFREY A. SOSMAN, MD
Atlanta, GA	THURSDAY, JANUARY 17, 2008	6:30-8:30 PM	Morton's, The Steakhouse Peachtree Lenox Building 3379 Peachtree Road N.E. Atlanta, GA 30326	RONALD BUKOWSKI, MD
Tampa, FL	THURSDAY, JANUARY 17, 2008	6:00-8:00 PM	The Palm Restaurant 205 Westshore Plaza Tampa, FL 33609	MICHAEL B. ATKINS, MD
Chicago, IL	TUESDAY, JANUARY 22, 2008	6:30-8:30 PM	Morton's, The Steakhouse 65 E. Wacker Place Chicago, IL 60601	RONALD BUKOWSKI, MD
Bethesda, MD	TUESDAY, JANUARY 22, 2008	6:00-8:00 PM	Morton's, The Steakhouse One Bethesda Metro 7400 Wisconsin Avenue Bethesda, MD 20814	ROBERT J. MOTZER, MD
Detroit, MI	WEDNESDAY, JANUARY 23, 2008	6:30-8:30 PM	Morton's, The Steakhouse One Town Square Southfield, MI 48076	RONALD BUKOWSKI, MD
Philadelphia, PA	WEDNESDAY, JANUARY 23, 2008	6:30-8:30 PM	Morton's, The Steakhouse 1411 Walnut Street Philadelphia, PA 19102	ROBERT J. MOTZER, MD
Nashville, TN	THURSDAY, JANUARY 24, 2008	6:30-8:30 PM	The Palm Restaurant 140 5th Avenue South Nashville, TN 37203	JEFFREY A. SOSMAN, MD
New York, NY	THURSDAY, JANUARY 24, 2008	6:30-8:30 PM	Morton's, The Steakhouse 551 5th Avenue New York, NY 10017	ROBERT J. MOTZER, MD
Houston, TX	MONDAY, JANUARY 28, 2008	6:30-8:30 PM	Morton's, The Steakhouse Centre at Post Oak 5000 Westheimer Road Houston, TX 77056	MICHAEL B. ATKINS, MD
Los Angeles, CA	TUESDAY, JANUARY 29, 2008	6:30-8:30 PM	The Palm Restaurant 9001 Santa Monica Blvd. Los Angeles, CA 90069	ROBERT FIGLIN, MD
Dallas, TX	TUESDAY, JANUARY 29, 2008	6:30-8:30 PM	Morton's, The Steakhouse 501 Elm Street Dallas, TX 75202	RONALD BUKOWSKI, MD

STATEMENT OF NEED

Approximately 51,000 new cases of cancer of the kidney and renal pelvis will be diagnosed in the United States in 2007. Patient prognosis varies considerably based on the stage of the disease at diagnosis. For patients who are diagnosed with local disease, 5-year survival rates reach almost 90%. Nephrectomy is the standard of care for local renal cell carcinoma (RCC). However, because RCCs remain clinically silent for much of their natural history, 30% of patients present with metastatic disease. Another 30% of patients who have undergone apparent curative resection of their primary tumor develop metastases. Median survival for patients with advanced or metastatic disease is 6-12 months, with a 2-year survival rate of 10%-20%.

For the past 20 years, cytokine therapy has been the mainstay of treatment for metastatic RCC, despite its toxicity, low response rate, and short survival benefit (only months). The potential for immunotherapy has been demonstrated with occasional spontaneous and dramatic remissions, but the poor outcomes experienced by the majority of patients with metastatic RCC underscore the need for more effective treatment. Because of an expanding understanding of the genetic and molecular basis of RCC, more than 80 new compounds are under development for treatment of advanced RCC. In particular, small molecules and monoclonal antibodies (MoAbs) that target and inhibit key signaling pathways involved in tumor growth, survival, and angiogenesis have demonstrated clinical benefit or are undergoing testing against standard cytokine therapy. This activity will review the results obtained by current therapeutic strategies as a backdrop to a detailed discussion of the clinical potential of current and emerging targeted agents for the treatment of RCC.

TARGET AUDIENCE

This activity is designed for oncologists, physicians, nurses, and other health care professionals interested in recent advances in the treatment of patients with renal cell carcinoma.

EDUCATIONAL OBJECTIVES

After participating in this educational activity, attendees should be able to:

1. Describe the aberrant signaling pathways characteristic of RCC.
2. Discuss the safety and efficacy of recently approved novel multitargeted agents for RCC.
3. Discuss recent clinical trials investigating the safety and efficacy of MoAbs in the treatment of RCC.
4. Describe recent clinical trials investigating the safety and efficacy of novel agents targeting single pathways for the treatment of RCC.

METHOD OF PARTICIPATION

This interactive dinner discussion/presentation forum, including key abstracts presented at the *43rd American Society of Clinical Oncology Annual Meeting*, will utilize multiple methods of participation to engage attendees and enhance the learning process.

ACCREDITATION

Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the Essential Areas and policies of the ACCME.

The CBCE designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The CBCE designates this educational activity for 1.5 contact hours. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

CERTIFICATE

The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

The CBCE gratefully acknowledges the educational grants received from multiple commercial supporters. To date, we have received educational grants from Genentech BioOncology, Novartis Pharmaceuticals Corporation, and Pfizer Oncology. Please visit www.thebce.com for a current list of supporters.

AMERICANS WITH DISABILITIES ACT (ADA)

The CBCE fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the registration desk or in the meeting room in order to request service.

EDUCATIONAL INQUIRIES

For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, Texas 75063; Telephone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thebce.com.

DISCLAIMER

The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE, Genentech BioOncology, Novartis Pharmaceuticals Corporation, or Pfizer Oncology. This material has been prepared based on a review of multiple sources of information, but is not exhaustive of the subject matter. Participants are advised to critically appraise the information presented, and are encouraged to consult the available literature on any product or device mentioned in this program.